Detalhe da pesquisa
1.
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Lancet Oncol
; 15(12): 1389-96, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25439693